X0202 SCHEDULE 13G 0001583977 XXXXXXXX LIVE Common Stock, par value $0.0001 per share 03/31/2026 0001739410 Rallybio Corp 75120L209 234 CHURCH STREET NEW HAVEN CT 06510 Rule 13d-1(b) Cormorant Asset Management, LP b DE 0.00 400000.00 0.00 400000.00 400000.00 N 7.56 IA PN Bihua Chen b X1 0.00 400000.00 0.00 400000.00 400000.00 N 7.56 HC IN Rallybio Corp 234 CHURCH STREET, NEW HAVEN, CT 06510 Cormorant Asset Management, LP Bihua Chen This statement is filed by (i) Cormorant Asset Management, LP, a Delaware limited partnership, and the investment adviser to certain funds (the "Cormorant Funds"), with respect to the shares directly held by the Cormorant Funds and (ii) Bihua Chen with respect to the shares directly held by the Cormorant Funds. The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons." The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the shares reported herein. 200 Clarendon Street, 52nd Floor Boston, MA 02116 Cormorant Asset Management, LP - Delaware Bihua Chen - United States N IA HC 400,000 7.56% 0 400,000 0 400,000 The percentages reported herein with respect to the Reporting Persons' holdings are calculated based upon a statement in the Issuer's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as filed with the Securities and Exchange Commission on March 16, 2026, that there were 5,289,675 shares of Common Stock of the Issuer outstanding as of March 6, 2026. Y N See Item 2. The Cormorant Funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares reported herein. Cormorant Global Healthcare Master Fund, LP, a Cormorant Fund, has the right to receive or the power to direct the receipt of dividends or the proceeds from the sale of more than 5% of the shares. Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning her or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that she or it knows or has reason to believe that such information is inaccurate. Dated: May 15, 2026 Cormorant Asset Management, LP By: Cormorant Asset Management GP, LLC its General Partner By: /s/ Bihua Chen Bihua Chen, Managing Member Bihua Chen By: /s/ Bihua Chen Bihua Chen Cormorant Asset Management, LP /s/ Bihua Chen 05/15/2026 Bihua Chen /s/ Bihua Chen 05/15/2026